Managing the transition from oral contraceptives to hormone replacement therapy

Oral contraceptives provide multiple benefits for perimenopausal women; the ir use results in considerable economic savings by managing vasomotor sympt oms, preventing pregnancy, and improving future outcomes. Hormone replaceme nt therapy provides many health benefits for menopausal women; a recently i ntroduced constant estrogen/intermittent progestin regimen takes advantage of receptor dynamics and the extended half-life of norgestimate to provide a continuous progestational effect on the endometrium. The lower progestin dose may also decrease progestin-related side effects and contribute to inc reased adherence and treatment continuation.